Very nice! Includes use of maraviroc and all other CCR5 inhibitors for treatment of viral infections (well many are listed but not sure about flu) with hyperinflammation component. Says maraviroc may also act as agonist of ccr5, so that may be one reason for some potential toxicity that leronlimab does not have.

I wonder if this patent includes treatment of long Covid?

Really pleased to see this granted. Lots to read.